1. |
McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain, 1987, 110(Pt 6): 1617.
|
2. |
Alessandro L, Pastor Rueda JM, Wilken MA, et al. Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. J Peripher Nerv Syst, 2018, 23(3): 154-158.
|
3. |
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet, 2016, 388(10045): 717-727.
|
4. |
Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve, 2010, 41(2): 202-207.
|
5. |
Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve, 2001, 24(3): 311-324.
|
6. |
Ruts L, van KR, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology, 2005, 65(1): 138-140.
|
7. |
Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the quality standards subcommittee of the American Academy of Neurology. Neurology, 2003, 61(6): 736-740.
|
8. |
中华医学会神经病学分会神经肌肉病学组, 中华医学会神经病学分会肌电图及神经电生理学组, 中华医学会神经病学分会神经免疫学组. 中国吉兰-巴雷综合征诊治指南. 中华神经科杂志, 2010, 43: 583-586.
|
9. |
RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol, 2009, 8(2): 158-164.
|